Identifai Genetics to IPO on Australian Exchange to Fund Genetic Testing
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
What happened
Identifai Genetics, an Israeli company, plans to debut on the Australian stock exchange on October 13, aiming to raise $10 million to fund the commercialization of its next-generation pre-natal tests. The company was founded based on research conducted by Professor Noam Shomron, who heads the functional genomics team at Tel Aviv University. Identifai uses a machine learning algorithm to screen for over 280 inherited genetic conditions using a single maternal blood draw.
Why it matters
The initial public offering is designed to raise capital for the commercialization of Identifai Genetics' prenatal testing services. The company utilizes artificial intelligence to compare a fetus's cell-free DNA with its mother's to detect disease-causing mutations.
Who's involved
- MillerBoss of Identifai Genetics
- Noam ShomronHead of the functional genomics team at Tel Aviv University and research founder of Identifai Genetics
- Tel Aviv UniversityUniversity where Professor Noam Shomron leads the functional genomics team
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- Tel Aviv UniversitySpeculative
The commercialization of the research might boost the university's prestige and funding access.
Keep exploring
The entities involved
- Miller
-
Noam Shomron
researcher
Nothing else this week.
-
Tel Aviv University
university in Tel Aviv, Israel
Nothing else this week.
-
Tel Aviv
city in Israel
- Strategic discussions involving Benjamin Netanyahu and the Atlantic Council regarding Iran, alongside escalating clashes with Hezbollah in Lebanon.
- Young Israelis are petitioning the High Court of Justice regarding their roots, which include births in Jerusalem and current residence in Tel Aviv, with parents having immigrated from the Philippines.